Bio

Andrew is an experienced healthcare investment professional with expertise identifying transformative products and technologies in all stages of development. Andrew is a Founding Partner of LifeSci Advisors and LifeSci Capital. Prior to founding LifeSci, Andrew serves as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004 – 2006 Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001 – 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at U.C. Berkley. Andrew holds the Series 7, 24, 63, 79, 86, and 87.